Carvedilol and the evolving management of portal hypertension in compensated cirrhosis
Journal of Clinical and Experimental Gastroenterology · 21.05.2026 · 5 (1) · 23
DOI: 10.46439/gastro.5.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Gastroenterology, online erschienen am 21.05.2026. Verfasst von Talha Khalid und 2 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Cirrhosis remains a major cause of liver-related mortality worldwide. The transition from compensated to decompensated disease, marked by complications such as ascites, hepatic encephalopathy, or variceal hemorrhage represents a critical shift in prognosis and survival. Clinically significant portal hypertension (CSPH) is the primary driver of this progression, making portal pressure reduction a central therapeutic target. For decades, non-selective beta-blockers (NSBBs) such as propranolol and nadolol have been used to lower portal pressure by reducing cardiac output and splanchnic blood flow. Carvedilol has recently emerged as a promising alternative because, in addition to β-adrenergic blockade, it also antagonizes α1 receptors, leading to intrahepatic vasodilation and greater reductions in hepatic venous pressure gradient. This commentary discusses the findings of a recent propensity score matched cohort study by Almasri et al., which compared carvedilol and propranolol in patients with compensated cirrhosis using a large real-world U.S. database. The study demonstrated a lower incidence of hepatic decompensation among patients receiving carvedilol and suggested a modest reduction in long-term mortality, although hospitalization rates were higher. These findings support a growing body of evidence favoring carvedilol as a first-line agent for portal hypertension. While observational data are increasingly compelling, randomized trials powered for clinical outcomes are still needed to definitively establish the optimal beta-blocker strategy in compensated cirrhosis.
Zitieren
APA
Khalid, T., Butt, M. A., & Malik, R. (2026). Carvedilol and the evolving management of portal hypertension in compensated cirrhosis. Journal of Clinical and Experimental Gastroenterology, 5(1), 23. https://doi.org/10.46439/gastro.5.031
Vancouver
Khalid T, Butt MA, Malik R. Carvedilol and the evolving management of portal hypertension in compensated cirrhosis. Journal of Clinical and Experimental Gastroenterology. 2026;5(1):23. doi:10.46439/gastro.5.031
BibTeX
@article{Khalid2026,
author = {Khalid, Talha and Butt, Muhammad Ali and Malik, Raza},
title = {Carvedilol and the evolving management of portal hypertension in compensated cirrhosis},
journal = {Journal of Clinical and Experimental Gastroenterology},
year = {2026},
volume = {5},
number = {1},
pages = {23},
doi = {10.46439/gastro.5.031}
}
EUVIMED